UNSPSC 51334203: Metiapine

This classification denotes an antipsychotic agent with the molecular formula C19H21N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 775D6D91J8, chemically known as 2-methyl-11-(4-methyl-1-piperazinyl)dibenzo(b,f)(1,4)thiazepine but generally known as metiapine, which bears US NIH Compound Identifier 22047. European Medicines Agency schedules Metiapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08882MIG.

UNSPSC 51334203 Metiapine is a Commodity code that captures pharmaceutical products procured by state and local health agencies, though the recent solicitations under this code show broader pharmaceutical and drug-management activity than the code name alone suggests. State and local governments are buying naloxone and drug deactivation systems for community health programs, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and exploring direct-to-manufacturer prescription fulfillment models to manage pharmacy benefit costs and improve supply-chain efficiency. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances serving participating state and local government facilities (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mix reflects both direct procurement by individual jurisdictions and participation in statewide or multistate cooperative vehicles that aggregate demand across multiple purchasing entities.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023—for a two-year initial term with one-year renewal option. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, gathering vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, a foundational information-gathering phase that will inform future formal solicitations. MMCAP posted RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with proposals due March 26, 2026, and awards effective July 1, 2026; evaluation weighting heavily favors price competitiveness (75 percent) and requires vendors to maintain relationships with at least two of the three wholesalers and comply with cGMP and Drug Supply Chain Security Act certification.